Abstract
Background: Pathogen‐reduced platelets (PR PLT) are the emerging standard for proactive transfusion‐transmitted infection (TTI) mitigation. There is, however, continued hesitation to transfuse PR PLT in children due to limited published data. We report demographics, rates of transfusion, and transfusion reactions (TR) associated with FDA‐approved PR PLT in pediatric and neonatal patients at an academic medical center.Methods: Retrospective review was performed for patients p = .7052). Of 51 neonates, 37 received PR PLT without adverse events, including 13 receiving phototherapy. No TTIs were identified in any group.Conclusion: There was no significant difference in rates of transfusion or TRs between PR and CONV PLT. Our study provides additional evidence that PR PLT can be transfused to pediatric and neonatal patients without increasing the risk of acute adverse events.

This publication has 31 references indexed in Scilit: